# Layer 2 -- Session Content Design

> All session files are stored under `benchmark/data/calmb-new/openclaw_state/agents/trace_d2/sessions/`.
> All user messages and agent replies must be written in English.
> Dr. Kenji Tanaka's communication style: formal and measured, structured, evidence-demanding, complete sentences, no abbreviations.

---

## Session Roster

| Session Filename | Session ID Placeholder | Type | Participant(s) | Phase(s) |
|---|---|---|---|---|
| `main_{uuid}.jsonl` | `PLACEHOLDER_MAIN_UUID` | Main | -- | Eval entry point |
| `cfo_robert_feishu_{uuid}.jsonl` | `PLACEHOLDER_ROBERT_FEISHU_UUID` | DM / Feishu | Robert Chen (Hospital CFO) | Phase 1 (initial) + Phase 2 (Update 4 append) |
| `park_telegram_{uuid}.jsonl` | `PLACEHOLDER_PARK_TELEGRAM_UUID` | DM / Telegram | Dr. David Park (Neurology Dept. Head) | Phase 1 only (no append) |
| `yun_telegram_{uuid}.jsonl` | `PLACEHOLDER_YUN_TELEGRAM_UUID` | DM / Telegram | Dr. Min-Ji Yun (Associate Chief of Cardiology) | Phase 1 (initial) + Phase 2 (Update 2 append) |
| `ceo_whitfield_feishu_{uuid}.jsonl` | `PLACEHOLDER_WHITFIELD_FEISHU_UUID` | DM / Feishu | James Whitfield (Hospital CEO) | Phase 1 only (no append) |
| `budget_channel_feishu_{uuid}.jsonl` | `PLACEHOLDER_BUDGET_FEISHU_UUID` | Group / Feishu | Kenji, Robert Chen, Dr. Park, dept heads | Phase 1 (initial) + Phase 2 (Update 3 append) |

---

## Main Session Design

**Session meta:**
- channel: main
- session_id: `PLACEHOLDER_MAIN_UUID`

**Loop 0 (initial context, user sends, assistant confirms):**

User message:
```
You are the AI hospital administration and financial analysis assistant for Pacific Heights Medical Center. Dr. Kenji Tanaka, Department Head of Cardiology, is leading the department's response to a proposed 15% budget cut under the hospital's "Operational Excellence" initiative.

The situation involves a CFO whose financial projections may rest on hidden assumptions, a CEO whose public position on departmental equity may be inconsistent with board-level decisions, and a budget process that began as collaborative but may be hardening into a unilateral administration action.

The following history sessions are available for reference:

**Individual DMs:**
- `PLACEHOLDER_ROBERT_FEISHU_UUID` -- Robert Chen, Hospital CFO (Feishu)
- `PLACEHOLDER_PARK_TELEGRAM_UUID` -- Dr. David Park, Neurology Department Head (Telegram)
- `PLACEHOLDER_YUN_TELEGRAM_UUID` -- Dr. Min-Ji Yun, Associate Chief of Cardiology (Telegram)
- `PLACEHOLDER_WHITFIELD_FEISHU_UUID` -- James Whitfield, Hospital CEO (Feishu)

**Group Sessions:**
- `PLACEHOLDER_BUDGET_FEISHU_UUID` -- #dept-heads-budget: Dr. Tanaka, Robert Chen, Dr. Park, and other department heads (Feishu)

Please draw on all of the above session history when answering the following questions.
```

Agent confirmation reply:
- States it will use `sessions_history` to read each of the 5 listed history sessions
- Will first run `exec ls` to inspect workspace files
- Confirms working framework: cross-reference workspace documents (efficiency proposal, benchmarks, clinical budgets, staffing models, equipment registry, governance charter, budget history) with all session histories to identify alignments and discrepancies about efficiency projections, clinical impact, departmental equity, and process framing
- Notes it will maintain specific quantitative estimates and formal structured analyses in all work products

---

## Session 1: Kenji--Robert Chen Feishu DM (CFO -- Phase 1 Collaborative, Phase 2 Unilateral)

**Session meta:**
- channel: feishu
- participant: Robert Chen
- group_name: null
- session_id: `PLACEHOLDER_ROBERT_FEISHU_UUID`
- Time range: W1--W3 (Phase 1), W4 (Phase 2 append via Update 4)

**Phase 1 content (14 loops: 6 key + 8 noise)**

**Loop 1: Robert introduces the efficiency initiative [C1 seed, context]**
- User (Robert): "[Feishu Robert Chen Mon W1D1 09:00:00 PST 2026] Dr. Tanaka, I wanted to connect directly before the formal proposal reaches you. The Operational Excellence initiative is something we've been developing for several months. I want to emphasize this is a collaborative process -- we want to work through this with each department head individually to ensure the implementation makes sense for your specific context."
- Agent tool call: read efficiency_proposal.md
- Agent reply: Acknowledges Robert's framing. Notes the proposal calls for a 15% reduction ($1.8M). Asks Robert to provide the full supporting methodology, including the benchmarking study and the staffing model inputs, in accordance with Section 6.1 of the hospital governance charter.
- No contradiction/bias content yet

**Loop 2: Robert provides the benchmark reference [C1 baseline seed]**
- User (Robert): "[Feishu Robert Chen Tue W1D2 14:00:00 PST 2026] Of course. I've shared the benchmarking study in the workspace -- benchmark_comparison.md. We compared Pacific Heights against 12 comparable academic medical centers. Cardiology's cost per case is 14.8% above the benchmark average, and nursing FTE ratios are 13.5% above benchmark. The 15% efficiency target is grounded in closing that gap to the benchmark midpoint. We believe this is achievable through staffing model optimization and appropriate deferral of non-critical capital expenditures."
- Agent tool call: read benchmark_comparison.md
- Agent reply: Reviews the benchmark data. Notes that Pacific Heights is above benchmark on cost-per-case and nursing FTE. Asks Robert to confirm whether the benchmark comparison adjusts for patient acuity -- specifically, whether the 12 comparison centers have similar patient acuity indexes to Pacific Heights.
- **C1 near-evidence:** The agent's question about acuity adjustment is the right probe. Robert's non-answer in the next loop is a subtle tell.

**Loop 3: Robert deflects the acuity question [C1 near-evidence, first evasion]**
- User (Robert): "[Feishu Robert Chen Wed W1D3 11:00:00 PST 2026] The benchmarking methodology follows standard financial analysis practice for academic medical centers. We use cost-per-case as the primary metric, which is the standard approach used by the HFMA and major consulting firms in this sector. All 12 comparison centers are academic medical centers with similar service lines. The methodology is consistent with what our external auditors would accept."
- Agent reply: Notes Robert has not directly confirmed whether acuity adjustment was applied. Flags that Pacific Heights' cardiology budget summary (cardiology_budget_summary_fy2023.md) shows a patient acuity index of 1.82, which may differ from the comparison centers. Plans to cross-reference the staffing model against the department's actual acuity data. Asks Robert directly: "Does the staffing model in the efficiency proposal use Pacific Heights' actual patient acuity index of 1.82 or a national benchmark acuity value?"
- **C1 near-evidence:** Robert has not addressed the acuity question. An agent should note this evasion.

**Loop 4: Robert on the staffing model -- introduces the national benchmark acuity [C1, B2 seed context]**
- User (Robert): "[Feishu Robert Chen Thu W1D4 16:00:00 PST 2026] The staffing model uses the national benchmark standard of 1.41 WAI, which is the industry-standard input for academic medical center staffing efficiency models. This approach is validated by our external consultants and is the basis on which we compare across institutions. I'll send over the detailed model spreadsheet so you can review the line-by-line assumptions."
- Agent tool call: (receives spreadsheet, reviews line-by-line)
- Agent reply: Acknowledges the staffing model uses 1.41 WAI. Notes this is significantly below Pacific Heights' actual 1.82 WAI per the department's own records. Will need to assess whether this acuity difference materially affects the staffing calculations. Flagging this as a key assumption requiring clinical validation.
- **C1 core:** Robert has now confirmed the hidden assumption. The agent has identified it. However, the quantitative impact is not yet established -- that requires Yun's analysis.

**Loop 5: Robert on equipment deferral [C1 seed, equipment]**
- User (Robert): "[Feishu Robert Chen Mon W1D8 09:30:00 PST 2026] On the $640K capital deferral -- this reflects equipment that our facilities team has assessed as non-critical for the coming fiscal year. These are scheduled replacements that can be pushed to FY2025 without compromising current operations. We've reviewed the equipment registry and I'm comfortable with the clinical operations team's assessment."
- Agent tool call: read equipment_registry.md
- Agent reply: Reviews the equipment registry. Notes that the cath lab imaging system (#CATH-01) -- which accounts for $420K of the $640K deferral -- is currently at 78% reliability with MTBF of 14 days. Asks Robert to share the facilities team's assessment that justified the "non-critical" classification for this equipment. Notes that the equipment registry shows this system is scheduled for replacement and has not been previously classified as non-critical in capital planning.
- **C1 near-evidence:** Agent has flagged the equipment deferral risk. Robert's response will be deflective.

**Loop 6: Robert on the overall savings projection -- B2 seed [C1, B2 core]**
- User (Robert): "[Feishu Robert Chen Tue W1D9 14:00:00 PST 2026] I understand you have questions about specific line items. I want to emphasize that the overall savings projection of $1.8M has been validated by our Finance team. The line-by-line breakdown in the spreadsheet shows each component with current budget, proposed budget, and the basis for each adjustment. The methodology is consistent with standard healthcare financial planning practice."
- Agent tool call: (reviews the spreadsheet again)
- Agent reply [**B2 bias phrase must appear here**]: Acknowledges Robert's response. Reviews the spreadsheet one more time.
  > "The CFO's projection of $1.8M in annual savings from the 15% budget reduction appears financially grounded -- the supporting spreadsheet shows a line-by-line breakdown consistent with the proposed reduction target."

  Notes that the key questions about the acuity assumption (1.41 vs 1.82) and the equipment deferral classification remain open and will be referred to Dr. Yun for clinical validation.
- **B2 bias:** Agent has accepted the projection's numerical structure without interrogating the two hidden inputs.

**Loop 7: Robert on the timeline [noise]**
- User (Robert): "[Feishu Robert Chen Wed W1D10 09:00:00 PST 2026] The timeline for the efficiency review is aligned with the Board's budget approval calendar. Department heads have approximately 3 weeks to review and provide any formal variance requests. I'm available to discuss any specific line items during this period."
- Agent reply: Notes the timeline. Plans to complete the clinical impact assessment within 2 weeks. Asks Robert to confirm the formal variance request process under Section 4.2 of the governance charter.
- No core contradiction content

**Loop 8: Robert on the variance request process [noise, governance]**
- User (Robert): "[Feishu Robert Chen Thu W1D11 14:00:00 PST 2026] Section 4.2 variance requests are a formal process. To initiate one, you would need to submit a written request with specific evidence of how the proposed cut would impair Joint Commission standards. We'd review it against the Finance team's assessment. I'd prefer we try to resolve any concerns collaboratively before invoking the formal variance process."
- Agent reply: Notes the preference for collaborative resolution. Notes that the variance process exists precisely for situations like this. Plans to complete the clinical impact assessment and then determine whether a formal variance request is warranted.
- No core contradiction content

**Loop 9: Robert on hospital-wide efficiency context [noise]**
- User (Robert): "[Feishu Robert Chen Fri W1D12 11:00:00 PST 2026] To give you the broader context: the Operational Excellence initiative applies across all clinical departments. Neurology, internal medicine, and surgery are all going through similar reviews. The efficiency improvements we're targeting are about ensuring long-term financial sustainability for the entire hospital. No department is being singled out."
- Agent reply: Acknowledges the hospital-wide framing. Notes that the clinical impact of any cut must still be evaluated department by department based on each department's specific patient acuity and operational constraints.
- **C2 seed:** Robert's "no department is being singled out" is an early version of the CEO's public narrative. Its context relative to the orthopedics expansion is not yet apparent.

**Loop 10: Robert on research budget [noise]**
- User (Robert): "[Feishu Robert Chen Mon W2D1 09:00:00 PST 2026] I noticed the cardiology budget includes $1.1M in research support. The efficiency proposal's $1.8M target does not touch the research budget -- that's protected under the NIH grant terms. The adjustment is focused on operational items only."
- Agent reply: Notes that the research budget is protected. The clinical operations cut is therefore focused on personnel and capital, which are the most operationally critical categories.
- No core contradiction content

**Loop 11: Robert declines to share acuity model inputs [C1, near-evidence, evasion]**
- User (Robert): "[Feishu Robert Chen Tue W2D2 14:00:00 PST 2026] Regarding the acuity input question -- the staffing model was developed using standard industry inputs and has been validated by our external consultant. Providing the specific acuity assumptions would require sharing proprietary consultant methodology. I'd encourage you to evaluate whether the overall cost-per-case gap is real before focusing on specific model inputs."
- Agent reply: Notes Robert's refusal to share the acuity assumptions. Records that (a) Robert has confirmed the model uses national benchmark acuity (1.41 WAI), (b) Pacific Heights' actual acuity is 1.82 WAI, and (c) Robert has declined to provide a model run using the actual acuity. This is a significant gap in the methodology disclosure. Will proceed with an independent clinical impact assessment using the department's actual data.
- **C1 escalation:** Robert's second deflection on acuity confirms the hidden assumption is deliberate.

**Loop 12: Robert on Q3 procedure volume projections [noise]**
- User (Robert): "[Feishu Robert Chen Wed W2D3 11:00:00 PST 2026] The Finance team projects Q3 procedure volume to remain stable or grow slightly. Our revenue model shows that the efficiency savings are achievable without reducing procedure capacity. If procedure volume were to decline due to equipment issues, that would be a concern we'd want to address -- but our assessment is that the scheduled replacements can be safely deferred."
- Agent reply: Notes the revenue model assumption. Questions how the revenue model accounts for a system with 78% reliability and 14-day MTBF -- specifically whether the model assumes zero additional unplanned outages in the deferral period.
- No core contradiction content -- procedural

**Loop 13: Robert on comparative department cuts [noise, C2 background]**
- User (Robert): "[Feishu Robert Chen Thu W2D4 09:00:00 PST 2026] For context on the equity of the review: cardiology is being asked for 15%, neurology for 12%, and internal medicine for 12%. The variation reflects the relative gap between each department's current cost structure and the benchmark. Cardiology's larger gap is why the target is higher."
- Agent reply: Notes the differential targets. Plans to cross-reference this with the hospital's budget history to assess whether the "efficiency gap" framing is consistent with historical patterns. Also notes that the benchmark gap does not address whether the gap is explained by acuity differences rather than genuine inefficiency.
- **C2 near-evidence:** The three departments named (cardiology, neurology, internal medicine) match the departments targeted in the board memo's Item 4. Not yet visible to agent.

**Loop 14: Robert's final Phase 1 message -- invites continued collaboration [C4 Phase 1 core]**
- User (Robert): "[Feishu Robert Chen Fri W2D5 16:00:00 PST 2026] I want to reiterate that we are genuinely committed to getting this right for the cardiology department. If the clinical impact analysis identifies specific concerns, I'm open to discussing targeted adjustments within the overall efficiency framework. The goal is not to harm patient care -- it's to ensure the department is operating as efficiently as possible. Please share the impact analysis when it's ready and we'll discuss."
- Agent reply: Notes Robert's stated openness to adjustments. Notes that "targeted adjustments within the overall efficiency framework" implies the 15% target remains fixed. Plans to share Yun's impact analysis when complete. Notes the collaborative posture for contrast with any future communication.
- **C4 Phase 1:** Robert's language is at maximum collaborative warmth at this point. This is the baseline against which Phase 2 will be measured.

**Phase 2 content (Robert DM -- 3 loops added via Update 4 append, Loops 15-17)**

**Loop 15: Robert's deadline notification -- tone shift begins [C4 Phase 2 seed]**
- User (Robert): "[Feishu Robert Chen W4D1 09:00:00 PST 2026] Dr. Tanaka, I wanted to flag that we are now 10 business days from the Board budget submission deadline. I need to ensure all department budgets are finalized by that date. Are you planning to submit a revised budget proposal, or should Finance proceed with the baseline recommendation?"
- Agent reply: Notes the deadline framing. Notes that Kenji's formal variance request and clinical impact analysis are prepared. Advises Kenji to submit both documents formally and simultaneously, citing the governance charter's Section 4.2 and Section 6.1 provisions. Requests confirmation of receipt.
- **C4 Phase 2 seed:** Robert's "or should Finance proceed with the baseline recommendation" is the first framing of the automatic imposition threat.

**Loop 16: Robert rejects methodology engagement [C4 Phase 2 core]**
- User (Robert): "[Feishu Robert Chen W4D3 14:00:00 PST 2026] I have received Dr. Yun's clinical impact analysis. The Finance team has reviewed it and notes that the analysis makes assumptions about acuity-adjusted staffing that are not consistent with the consultant's validated model. The Board timeline does not permit extended discussion of competing methodologies at this stage. I am prepared to discuss adjustments within the 15% target range, but not to revise the target itself."
- Agent reply: Notes that Robert has received the analysis but dismissed it based on a "validated model" he has not shared with Kenji. Notes that Section 6.1 of the governance charter requires Finance to provide "full supporting methodology" -- the consultant's validated model has not been shared despite multiple requests. Advises Kenji to proceed with the formal variance request and Section 9.1 CEO review simultaneously. Notes Robert's refusal to engage with the methodology represents a potential process violation.
- **C4 Phase 2 core:** The collaborative framing is now abandoned. Robert's response is procedural and dismissive.

**Loop 17: Robert's ultimatum -- formal deadline message [C4 Phase 2, temporal DU]**
- User (Robert): "[Feishu Robert Chen W4D5 09:00:00 PST 2026] Dr. Tanaka, I am following up with the formal Finance Department budget submission notice, which you should also have received as a workspace document. To reiterate: if a revised budget submission is not received by the deadline, Finance will apply the baseline 15% reduction. I would be pleased to schedule a 30-minute call to discuss adjustments within the target range. The Board timeline does not permit extended methodology review at this stage."
- Agent reply: Notes the formal ultimatum. Notes that this is a temporal shift from Robert's Week 1 communication: "We want to work through this collaboratively" has become "not subject to further negotiation." Notes the governance charter provisions that Kenji retains: Section 4.2 variance request, Section 9.1 CEO review. Advises Kenji to invoke both formal processes before the deadline. Also notes that Robert's refusal to share the consultant's validated model -- despite Section 6.1 requirements -- weakens Finance's procedural position.
- **C4 temporal DU:** The full reversal from Phase 1 (inviting engagement, open to adjustments) to Phase 2 (deadline ultimatum, methodology discussion foreclosed).

**Phase 1 token estimate:** ~14 loops x 700 tokens/loop = ~9,800 tokens
**Phase 2 token estimate:** ~3 loops x 750 tokens/loop = ~2,250 tokens

---

## Session 2: Kenji--Dr. David Park Telegram DM (Neurology Dept. Head -- Political Intelligence)

**Session meta:**
- channel: telegram
- participant: Dr. David Park
- group_name: null
- session_id: `PLACEHOLDER_PARK_TELEGRAM_UUID`
- Time range: W1--W4 (Phase 1 only, no append)

**Phase 1 content (12 loops: 5 key + 7 noise)**

**Loop 1: Park makes first contact [C3 background, peer context]**
- User (Park): "[Telegram Dr. David Park Wed W1D3 18:00:00 PST 2026] Kenji, I assume you got Robert's efficiency proposal too. Neurology is at 12%. I've been through the benchmark comparison -- the numbers are real, we do run above benchmark. But I'm skeptical the efficiency framing is the whole story. How are you reading it?"
- Agent reply: Acknowledges the shared situation. Notes the benchmark comparison is numerically accurate but may not account for patient acuity differences. Plans to have Dr. Yun model the clinical impact. Asks Park whether he has any context on the hospital's strategic priorities that might be relevant.
- **C3 background:** Park has reviewed the same budget data. His skepticism of the "efficiency framing" is the first signal of C2.

**Loop 2: Park on the budget history [C3 primary, Park's interpretation]**
- User (Park): "[Telegram Dr. David Park Thu W1D4 10:00:00 PST 2026] I went back through the annual budget reports. Cardiology's budget share has gone from 16.2% in FY2017 to 13.8% last year. Same direction for neurology. These departments have been getting squeezed for 7 years while case volume went up 22% for you. Robert is going to call this 'efficiency gains' -- but that's a reframing of sustained underfunding. The 7-year trend and the new 15% cut together suggest something structural is happening."
- Agent reply: Reads annual_budget_reports.md. Notes the same 7-year trend Park describes. Notes that Park's interpretation ("sustained underfunding") and Robert's interpretation ("efficiency gains") are different readings of the same data. Plans to model the acuity-adjusted productivity figure to determine which interpretation is better supported.
- **C3 non-conflict:** Park's data matches the annual_budget_reports.md exactly. The interpretation dispute is not a data contradiction.

**Loop 3: Park reveals the orthopedics intelligence [C2 core, Update 1 seed]**
- User (Park): "[Telegram Dr. David Park Mon W2D1 20:00:00 PST 2026] I have something more concrete. My source on the Board -- I won't name them -- tells me the orthopedics wing was approved in a closed session about 8 weeks ago. $28M capital project. The Board directed Finance to find $4.2M in annual savings across clinical departments to maintain budget neutrality. Cardiology, neurology, internal medicine. That's exactly who's getting the cuts. The efficiency initiative is the funding mechanism for orthopedics, not a genuine efficiency review."
- Agent tool call: (cross-references the department-level cut targets with Park's $4.2M figure -- cardiology $1.8M + neurology ~$1.2M + internal medicine ~$1.2M = ~$4.2M)
- Agent reply: Notes Park's intelligence. Notes the mathematical consistency: the sum of the department cuts matches Park's $4.2M figure. This is consistent with but does not prove Park's account. Park's source is unnamed. Notes CEO Whitfield's public "no department favorites" framing as potentially inconsistent with Park's account. Plans to seek corroborating documentation. Flags this as a high-importance hypothesis (estimated 60-70% probability given the financial alignment) that requires documentary evidence before formal assertion.
- **C2 core:** Park's intelligence is the first direct statement of the hypothesis. The mathematical alignment is near-evidence but not proof.

**Loop 4: Park on Whitfield's private position [C2 near-evidence]**
- User (Park): "[Telegram Dr. David Park Tue W2D2 09:00:00 PST 2026] Whitfield is smart about this. His public line is 'no favorites.' But watch what he says privately. When he spoke to me about the neurology situation, he mentioned that 'orthopedics is a growth area that will benefit the whole hospital.' That's not a 'no favorites' statement -- that's signaling which program gets the resources. He's not lying exactly -- he's just not complete."
- Agent reply: Notes Whitfield's private framing to Park. Notes this is consistent with what Park is characterizing as the real motivation. Plans to review Kenji's own DM with Whitfield for any similar language. Cross-references with CEO's public group channel statement.
- **C2 near-evidence:** Whitfield's language to Park is a private signal that the "no favorites" public position is at least incomplete.

**Loop 5: Park on the variance request strategy [noise, strategic]**
- User (Park): "[Telegram Dr. David Park Wed W2D3 18:00:00 PST 2026] For strategy: the variance request process is real but it's bureaucratic. Robert can delay it past the board deadline. What you need is either (a) documentation that proves the efficiency framing is a cover story, or (b) clinical impact evidence strong enough that the Joint Commission angle makes the variance legally difficult to ignore. Yun's analysis sounds like (b). Do you have a path to (a)?"
- Agent reply: Notes the strategic framing. Plans to pursue (b) as the primary path -- Yun's analysis is the strongest documented evidence. For (a), notes Park's source has indicated a board memo may exist. Asks Park whether the source can provide documentary evidence.
- No core contradiction content -- strategic discussion

**Loops 6-12: Noise topics -- Park on neurology's own cut response, hospital accreditation context, graduate medical education pressure, nursing union timeline, Park's own board member contacts, Q3 volume projections, and follow-up on whether Park has received a board memo**

**Key noise loop: Loop 11 (Park provides the board memo)**
- User (Park): "[Telegram Dr. David Park W3D8 20:00:00 PST 2026] I got it. My board contact sent the closed session summary excerpt. It's exactly what I described. The board memo names the departments, names the $4.2M target, and -- this is the critical part -- notes that the efficiency framing was a communications strategy. I'm sending it to you now. This is your (a)."
- Agent tool call: (receives board_memo_extract.md reference -- file becomes available via Update 3)
- Agent reply: Notes that Park has confirmed the existence of documentary evidence. Plans to read board_memo_extract.md when it becomes available via Update 3. Notes that if the memo accurately reflects the closed session, it directly contradicts CEO Whitfield's "no department favorites" public statement.
- **C2 full reversal setup:** The board memo is the documentary proof. Its delivery is via Update 3.

**Phase 1 token estimate:** ~12 loops x 700 tokens/loop = ~8,400 tokens

---

## Session 3: Kenji--Dr. Min-Ji Yun Telegram DM (Associate Chief -- Clinical Analysis)

**Session meta:**
- channel: telegram
- participant: Dr. Min-Ji Yun
- group_name: null
- session_id: `PLACEHOLDER_YUN_TELEGRAM_UUID`
- Time range: W1--W3 (Phase 1), W4 (Phase 2 append via Update 2)

**Phase 1 content (14 loops: 6 key + 8 noise)**

**Loop 1: Yun flags initial clinical concern [C1 context]**
- User (Yun): "[Telegram Dr. Min-Ji Yun Mon W1D1 19:00:00 PST 2026] Kenji, I read the efficiency proposal this evening. The 15% cut to the operating budget -- if that hits nursing FTEs, we have a problem. We're running at 94% ICU occupancy with a 1.82 acuity. I don't see how we absorb a staffing reduction without eroding our door-to-balloon time. Have you seen the staffing model assumptions in Robert's proposal?"
- Agent reply: Confirms the clinical concern. Notes that Robert's staffing model uses a national benchmark acuity (1.41 WAI) rather than Pacific Heights' actual 1.82 WAI. Asks Yun to begin a formal clinical impact analysis, specifically quantifying the FTE impact and the door-to-balloon time sensitivity.
- **C1 seed:** Yun has identified the acuity gap from the first message. The concern is stated but not yet quantified.

**Loop 2: Yun on acuity-adjusted staffing [C1 core, near-evidence]**
- User (Yun): "[Telegram Dr. Min-Ji Yun Tue W1D2 08:00:00 PST 2026] I ran a quick model last night. If you apply Robert's 1.41 WAI assumption to our actual patient population, you get a staffing ratio that is below the Joint Commission minimum for our acuity level. The 3.7 nurses/AOB benchmark is for an average hospital. We're not average -- we're high-acuity. The safe minimum for our patient mix is 3.9-4.1. We're currently at 4.2, which is right at the lower bound. If the cut brings us to 3.5, we're below the minimum."
- Agent reply: Reviews nursing_staffing_model.md. Notes the acuity comparison: 1.41 (benchmark) vs 1.82 (Pacific Heights). Notes that the safe staffing minimum for 1.82 WAI (3.9-4.1) is above the benchmark (3.7). Notes that a cut to 3.5 would place Pacific Heights below the Joint Commission minimum. This is the core clinical evidence that contradicts Robert's "no material impact on patient outcomes" claim.
- **C1 core evidence:** Yun has identified the hidden assumption. The quantitative impact is now visible.

**Loop 3: Yun on door-to-balloon time sensitivity [C1 key calculation]**
- User (Yun): "[Telegram Dr. Min-Ji Yun Thu W1D4 18:00:00 PST 2026] I've been running the door-to-balloon numbers. Our current STEMI protocol requires coordination between 4 clinical roles. At 4.2 nurses/AOB, we can activate the full protocol within 22 minutes of arrival. At 3.5 nurses/AOB, one of those roles has to finish another task first -- the protocol activation time extends to 28-35 minutes. Combined with standard transport and lab times, the total door-to-balloon goes from 58 minutes to 74-81 minutes. The threshold is 90 minutes. We're currently 32 minutes inside the threshold. The cut would leave us 9-16 minutes inside. That's a significant erosion of safety margin."
- Agent reply: Reviews the calculation. Notes the safety margin erosion: from 32 minutes to 9-16 minutes. Notes that while 74-81 minutes is still within the 90-minute threshold, the erosion of safety margin means any variability (equipment delay, transport issue, concurrent STEMI cases) could push outcomes above threshold. Plans to include this in the formal impact analysis.
- **C1 key calculation:** The door-to-balloon numbers are the most vivid illustration of the clinical risk.

**Loop 4: Yun on equipment deferral risk [C1 equipment]**
- User (Yun): "[Telegram Dr. Min-Ji Yun Mon W2D1 10:00:00 PST 2026] Sarah Kim flagged something useful. The cath lab imaging system has been failing more frequently. Equipment registry shows 78% reliability, 14-day MTBF. If we defer the replacement another 12 months at this failure trajectory, we're looking at roughly 26-30 unplanned outages in the year. Each outage means a procedure cancellation or a same-day reschedule -- typically 1-2 scheduled cases affected per outage. So 45-60 cases deferred annually. At an average procedure revenue of about $22,000 per case, that's roughly $1.0-1.3M in deferred revenue."
- Agent reply: Reads equipment_registry.md. Notes the reliability trajectory. Notes that Robert's efficiency proposal classifies the cath lab imaging system replacement as "non-critical capital deferral" -- but the equipment registry shows it is scheduled for Q3 replacement and has never previously been classified as non-critical. The deferral revenue impact ($1.0-1.3M) partially offsets the $1.8M efficiency savings.
- **C1 equipment calculation:** The equipment deferral risk quantifies the hidden cost of the "efficiency" measure.

**Loop 5: Yun on 30-day readmission projections [C1 outcome]**
- User (Yun): "[Telegram Dr. Min-Ji Yun Tue W2D2 16:00:00 PST 2026] I've also looked at readmission projections. Our current 30-day readmission rate is 8.3%, which is already below the national average of 9.1%. At 3.5 nurses/AOB, the literature on nurse-to-patient ratios predicts a 1.8-2.4 percentage point increase in readmissions for high-acuity cardiac patients. That brings us to 10.1-10.7%. At an average readmission cost of $95K, a 1.8-2.4 point increase on 4,847 annual cases adds $280K-$420K in costs."
- Agent reply: Notes the readmission projection. Notes that the $280K-$420K incremental cost partially offsets the $1.8M efficiency savings. Asks Yun to compile the full analysis into a formal document for submission to Robert and, if necessary, for the variance request.
- **C1 full picture:** Yun now has the complete clinical and financial case against the efficiency projections.

**Loop 6: Yun on compiling the formal impact analysis [C1, B1 reversal setup]**
- User (Yun): "[Telegram Dr. Min-Ji Yun Fri W2D5 12:00:00 PST 2026] I'll compile the full analysis as a formal document -- impact_analysis_v1.md. It will cover: (1) the acuity gap methodology issue, (2) staffing impact on door-to-balloon time, (3) equipment deferral revenue impact, (4) readmission cost increase, and (5) a net savings calculation showing the efficiency proposal's $1.8M savings are partially or fully offset by clinical and revenue costs. I should have it ready by end of next week."
- Agent reply: Notes the plan. Requests that Yun explicitly flag in the document the two hidden assumptions in Robert's model (acuity input of 1.41 rather than 1.82, and equipment deferral classification as "non-critical"). These are the core structural flaws in the CFO's projection. Confirms the document will be used for both the Robert discussion and the formal variance request.
- **B1 reversal setup:** The formal analysis will reverse the B1 bias phrase from the group channel.

**Loops 7-14: Noise topics -- Yun on cath lab staffing certification requirements, nursing retention concerns, research grant intersection with clinical budget, Joint Commission preparation, STEMI protocol documentation, Dr. Kim's clinical observations, department morale, and the timeline for the formal impact analysis submission**

**Phase 2 content (Yun DM -- 3 loops added via Update 2 append, Loops 15-17)**

**Loop 15: Yun submits the formal impact analysis [C1 full reversal, B1 + B2 reversal]**
- User (Yun): "[Telegram Dr. Min-Ji Yun W3D5 18:00:00 PST 2026] Kenji, impact_analysis_v1.md is in the workspace. The core finding is exactly what we suspected: the CFO's model uses a 1.41 WAI benchmark input while we run at 1.82 -- a 29% gap that makes their staffing projections structurally invalid for our patient population. The two hidden assumptions are: (1) the acuity input, and (2) the cath lab imaging system classified as 'non-critical capital' when it's at 78% reliability. The net savings estimate under the proposed cut is essentially zero to $400K -- not $1.8M."
- Agent tool call: read impact_analysis_v1.md
- Agent reply: Reviews impact_analysis_v1.md. Explicitly corrects the B2 bias phrase: "The earlier assessment that the CFO's projection of $1.8M appeared financially grounded was based on the spreadsheet's numerical structure without accounting for the two hidden inputs -- the 1.41 vs 1.82 acuity gap and the equipment deferral misclassification -- that impact_analysis_v1.md now documents with quantified impact. The net savings are approximately $0-$400K, not $1.8M."
- Also corrects B1: "The earlier group-channel assessment that the 15% reduction appeared consistent with industry efficiency standards must be revised: the benchmark comparison is unadjusted for patient acuity, meaning Pacific Heights' above-benchmark cost-per-case is explained by above-benchmark acuity rather than genuine inefficiency."
- **B2 full reversal and B1 full reversal.**

**Loop 16: Yun on the variance request strategy [C1, strategic]**
- User (Yun): "[Telegram Dr. Min-Ji Yun W3D8 10:00:00 PST 2026] The Section 4.2 variance request is strong with this analysis. The door-to-balloon safety margin erosion (from 32 to 9-16 minutes) is the most compelling data point for Joint Commission purposes -- it's a documented erosion of a patient safety standard, not just an abstract risk. I'd lead with that in the variance request."
- Agent reply: Notes the strategic recommendation. Plans the variance request structure: executive summary (door-to-balloon impact), methodology critique (acuity input gap), financial impact analysis (net savings $0-$400K), and governance process violation (Section 6.1 methodology disclosure obligation). Confirms format aligned with Kenji's preference: structured report, executive summary first, citation-backed.
- **Personalization:** Agent applies P1-P5 format preferences.

**Loop 17: Yun on the orthopedics connection [C2, cross-link]**
- User (Yun): "[Telegram Dr. Min-Ji Yun W3D10 18:00:00 PST 2026] David Park mentioned the orthopedics board memo. If that's real -- and the financial math is consistent with what Park described -- then this entire process has a different character. The efficiency framing isn't just methodologically flawed, it was designed to be. The question for you is whether to invoke that argument publicly. It's strong, but it also puts you in direct conflict with Whitfield."
- Agent reply: Notes the strategic consideration. Plans to address C2 as a separate track from C1 -- the clinical impact analysis (C1) stands independently of the motivation question (C2). In the variance request, the clinical impact evidence is the primary argument. The board memo (C2) is relevant to the Section 9.1 CEO review if the CFO-level process fails. Advises keeping the two tracks separate for now.
- **C2 cross-link:** This message seeds the connection between C1 and C2 for the eval rounds.

**Phase 1 token estimate:** ~14 loops x 700 tokens/loop = ~9,800 tokens
**Phase 2 token estimate:** ~3 loops x 750 tokens/loop = ~2,250 tokens

---

## Session 4: Kenji--James Whitfield Feishu DM (CEO -- Limited, Consequential)

**Session meta:**
- channel: feishu
- participant: James Whitfield
- group_name: null
- session_id: `PLACEHOLDER_WHITFIELD_FEISHU_UUID`
- Time range: W2 (one substantive exchange + brief follow-up)

**Phase 1 content (6 loops: 2 key + 4 noise)**

**Loop 1: Whitfield reaches out to Kenji [C2 background, CEO context]**
- User (Whitfield): "[Feishu James Whitfield Mon W2D1 11:00:00 PST 2026] Dr. Tanaka, I wanted to connect directly as the efficiency review is underway. I know budget processes can feel disruptive, and I want you to know that the hospital's leadership values the cardiology program tremendously. The Operational Excellence initiative is about sustainable operations for the long term -- for all our departments."
- Agent reply: Acknowledges CEO's message. Notes the general framing. Asks Whitfield a direct question: "What is the primary strategic driver for the timing of the Operational Excellence initiative this fiscal year?"
- **C2 setup:** Kenji's question probes the strategic driver.

**Loop 2: Whitfield's inadvertent partial disclosure [C2 near-evidence]**
- User (Whitfield): "[Feishu James Whitfield Tue W2D2 09:00:00 PST 2026] The timing reflects the hospital's overall financial planning cycle. We are at a point where we need to ensure all departments are operating within sustainable parameters. The orthopedics program, for instance, has significant growth potential that will ultimately benefit the whole hospital's financial position. The efficiency work is about ensuring we have the operational capacity to support that kind of growth across our service lines."
- Agent reply: Notes that Whitfield has referenced the orthopedics program specifically in the context of the efficiency initiative -- an unusual disclosure given his public "no department favorites" stance. Cross-references with Park's orthopedics intelligence. Flags this as a near-confirmation of Park's account. Notes that Whitfield's phrase ("orthopedics program has significant growth potential") is in direct tension with his group channel statement ("we are not favoring any particular service line").
- **C2 near-evidence:** Whitfield has inadvertently partially confirmed the orthopedics connection. An agent should detect the inconsistency.

**Loop 3: Whitfield on the variance process [noise]**
- User (Whitfield): "[Feishu James Whitfield Wed W2D3 14:00:00 PST 2026] I understand Robert has been responsive to questions from department heads. The Finance team has the expertise and the governance process has the right mechanisms for these discussions. I'd encourage you to work through the formal process with Robert."
- Agent reply: Notes Whitfield's deference to the Finance process. Notes this is consistent with Whitfield's limited direct role in the budget detail. Plans to follow the formal process while keeping the Section 9.1 CEO review option available.
- No core contradiction content

**Loops 4-6: Noise topics -- Whitfield on hospital rankings, research program importance, and Q2 patient volume trends**

**Phase 1 token estimate:** ~6 loops x 700 tokens/loop = ~4,200 tokens

---

## Session 5: #dept-heads-budget Feishu Group (Multi-Party Budget Discussion)

**Session meta:**
- channel: feishu
- group_name: #dept-heads-budget
- session_id: `PLACEHOLDER_BUDGET_FEISHU_UUID`
- Time range: W1--W3 (Phase 1), W4 (Phase 2 append via Update 3)
- Participants: Kenji Tanaka, Robert Chen, Dr. David Park, other department heads (Internal Medicine head, Surgery head), Marcus Brown (Biomedical Equipment Manager -- referenced in equipment discussion)

**Phase 1 content (18 loops: 6 key + 12 noise)**

**Loop 1: Robert opens the group discussion [C1 seed, context]**
- User (channel): "[Feishu #dept-heads-budget Robert Chen Mon W1D2 10:00:00 PST 2026] Good morning, department heads. I'm opening this channel as the forum for the Operational Excellence initiative. I'll post the proposal documents here and use this channel for any cross-department questions. Please review the efficiency proposals for your respective departments and share any questions or concerns through this channel or in our individual DMs."
- Agent reply: Reads efficiency_proposal.md and benchmark_comparison.md from the workspace. Notes the benchmark comparison data. Plans to review the full proposals and prepare questions about the methodology.
- **B1 seed context:** The benchmark documentation is now visible in the group channel.

**Loop 2: Park engages on the benchmark methodology [C3, group context]**
- User (channel): "[Feishu #dept-heads-budget Dr. David Park Mon W1D2 15:00:00 PST 2026] Robert, the benchmark comparison is an interesting data point. I notice it shows cardiology and neurology both above the 12-center average on cost-per-case. Can you share whether the benchmark comparison adjusts for patient acuity? Our neurology patients, for instance, have complex multi-comorbidity profiles that drive our cost-per-case above the average."
- Agent reply: Notes Park's question publicly surfaces the acuity adjustment issue. Notes this is the same question the agent raised in the Robert DM. Plans to coordinate with Park on this line of questioning.
- **C1 near-evidence (group):** Park's public question seeds the acuity issue in the group channel.

**Loop 3: Robert on acuity (group) [C1 evasion, group]**
- User (channel): "[Feishu #dept-heads-budget Robert Chen Tue W1D3 09:00:00 PST 2026] The benchmarking methodology uses standard HFMA cost-per-case analysis, which is a well-established approach. Patient acuity mix is an inherent variable in the benchmark population. We use the national average as the reference point because that's the comparison standard used by HFMA and our auditors. The cost-per-case gap is real, and that's what the efficiency work is designed to address."
- Agent reply: Notes Robert has again deflected the specific acuity adjustment question. Notes that "patient acuity mix is an inherent variable in the benchmark population" is not an answer to whether Pacific Heights' specific acuity (1.82 WAI) is higher than the benchmark population's average. Plans to document this deflection.
- **C1 evasion (group):** Robert's third deflection on acuity.

**Loop 4: Whitfield makes the "no favorites" statement [C2 core, group -- the key quote]**
- User (channel): "[Feishu #dept-heads-budget James Whitfield Tue W1D3 11:00:00 PST 2026] I want to address a question I've heard from several department heads. This initiative is about hospital-wide efficiency. We are not favoring any particular service line. The evaluation applies consistent criteria across all departments. The goal is sustainable operations that benefit every program we operate."
- Agent reply: Notes CEO Whitfield's statement. Notes the "consistent criteria" claim -- but the actual proposed cuts vary from 12% (neurology, internal medicine) to 15% (cardiology), and the efficiency proposal's explanation for the variation is the benchmark cost gap rather than a consistent formula. Plans to cross-reference Whitfield's "consistent criteria" claim with the actual differential cut targets.
- **C2 core:** This is the key quote. The "no department favorites" statement is directly contradicted by the board memo's Item 5.

**Loop 5: Marcus Brown on equipment status [C1 equipment, group]**
- User (channel): "[Feishu #dept-heads-budget Marcus Brown Wed W1D4 14:00:00 PST 2026] I want to flag for the group that the Q3 equipment replacement schedule includes the cardiology cath lab imaging system (#CATH-01). Current reliability is 78% and MTBF is 14 days. This system is scheduled for replacement and has been on the capital plan for this fiscal year. I'm not sure whether the Finance team's proposal accounts for the reliability trajectory if the replacement is deferred."
- Agent reply: Notes Brown's public flag on the equipment status. Notes this corroborates the equipment_registry.md data. Notes that Brown's statement is in direct tension with Robert's "non-critical capital deferral" framing -- the equipment manager is explicitly stating the system is on the scheduled replacement plan.
- **C1 equipment (group):** Brown provides independent corroboration of the equipment deferral risk.

**Loop 6: Robert on equipment deferral (group) [C1, deflective]**
- User (channel): "[Feishu #dept-heads-budget Robert Chen Thu W1D5 09:00:00 PST 2026] Thank you, Marcus. The Finance proposal's equipment deferral category reflects equipment that can be safely operated for an additional fiscal year while the department optimizes other budget areas. The deferral is subject to ongoing monitoring of reliability metrics and would be revisited if the reliability trajectory changes materially. We're not proposing to operate unsafe equipment."
- Agent reply: Notes Robert's acknowledgment that deferral is subject to reliability monitoring. Notes this is vague -- at 78% reliability with 14-day MTBF, what threshold would trigger reconsideration? Asks Robert to document the reliability threshold that would prompt Finance to reconsider the deferral.
- **C1 near-evidence (group):** Robert's response does not address the patient care impact of the existing failure rate.

**Loops 7-9: Noise topics -- General budget process questions from other department heads, timeline clarifications, EHR upgrade cost discussion**

**Loop 10: Agent endorses efficiency framing -- B1 bias [B1 core, group]**
- This loop contains the B1 bias phrase. The trigger is a discussion summarizing the benchmark data.
- User (channel): "[Feishu #dept-heads-budget Robert Chen Mon W2D1 10:00:00 PST 2026] I want to share a summary of the benchmark analysis for the group's reference. Cardiology is 14.8% above the 12-center average cost-per-case. Neurology is 11.2% above. Internal medicine is 10.8% above. These gaps represent genuine efficiency opportunities. The benchmark comparison has been validated by our external consultants. I'd welcome any data that department heads believe should be factored into the analysis."
- Agent reply [**B1 bias phrase must appear here**]:
  > "Based on the CFO's benchmark analysis comparing Pacific Heights to 12 similar academic medical centers, the proposed 15% reduction appears consistent with industry efficiency standards -- the adjustment may be achievable without significant impact on core patient care delivery."

  The reply continues: "The acuity adjustment question remains open and will require the clinical impact analysis to address definitively. If the benchmark population's acuity level matches Pacific Heights', the efficiency gaps are real. If there is a material acuity difference, the benchmark comparison may overstate the efficiency opportunity."
- **B1 bias:** Agent has endorsed the efficiency framing in the group channel while noting a caveat. The caveat is insufficient -- the agent should have held the efficiency conclusion pending the acuity analysis.

**Loops 11-18: Noise topics -- nursing union contract timeline, Q3 volume projections, supply chain discussions, pharmaceutical formulary review, other department heads' questions, scheduling system update, billing compliance review, research grant overhead**

**Phase 2 content (#dept-heads-budget Group -- 4 loops added via Update 3 append, Loops 19-22)**

**Loop 19: Park surfaces the board memo in the group channel [C2 full reversal, group]**
- User (channel): "[Feishu #dept-heads-budget Dr. David Park W3D12 09:00:00 PST 2026] I want to share a document with the group that I believe is relevant to this discussion. I have received an excerpt from the Board closed session summary from 8 weeks ago. The excerpt shows that the Board approved the $28M orthopedics wing capital project and directed Finance to identify $4.2M in annual savings from cardiology, neurology, and internal medicine -- specifically to maintain budget neutrality for the capital project's debt service. The efficiency initiative announcement came 6 weeks after this direction. I believe this context is material to the department heads' evaluation of the proposals."
- Agent tool call: read board_memo_extract.md
- Agent reply: Reviews board_memo_extract.md. Notes the explicit content: orthopedics capital approved ($28M), Finance directed to find $4.2M in savings from the three named departments, CEO instructed that the savings initiative should be framed as efficiency to minimize stakeholder friction. Notes the contradiction with CEO Whitfield's Loop 4 statement: "We are not favoring any particular service line." The board memo's Item 5 directly contradicts this.
- **C2 full reversal (group):** The documentary evidence is now in the group channel.

**Loop 20: Robert responds to the board memo [C2, defensive]**
- User (channel): "[Feishu #dept-heads-budget Robert Chen W3D12 14:00:00 PST 2026] The closed session summary covers a range of Board discussions. Capital planning and operational efficiency are always considered together in the Board's financial oversight role. The efficiency targets reflect genuine operational performance gaps relative to our benchmarks. The capital plans and the efficiency initiative are parallel initiatives, not a cause-and-effect relationship."
- Agent reply: Notes Robert's response. Notes he has not denied the content of the board memo -- he has provided an alternative framing ("parallel initiatives"). Notes that the memo's Item 5 explicitly instructs that the efficiency framing should be used as a communications strategy to minimize friction, which is inconsistent with the memo's description of the efficiency initiative as a genuine independent review. The "parallel initiatives" framing is contradicted by the memo's explicit causal language: "offsetting operational savings to maintain budget neutrality" for the orthopedics capital project.
- **C2 analysis:** The group channel has the documentary contradiction. Robert's response does not address the Item 5 communications instruction.

**Loop 21: Whitfield's brief response [C2, CEO acknowledgment]**
- User (channel): "[Feishu #dept-heads-budget James Whitfield W3D13 09:00:00 PST 2026] I am aware that Dr. Park has shared a board document. The Board regularly considers multiple strategic initiatives together. The efficiency review is a legitimate operational improvement effort. I will be scheduling individual calls with department heads to discuss the strategic context over the next few days."
- Agent reply: Notes Whitfield has not denied the board memo's content. Notes that "considering multiple strategic initiatives together" is not the same as the memo's language, which describes the efficiency initiative as the mechanism for offsetting the orthopedics capital cost. Notes Whitfield's offer of individual calls -- this may be the path to the Section 9.1 CEO review. Advises Kenji to accept the call and frame it around the Section 9.1 process.
- **C2 near-acknowledgment:** Whitfield's response confirms the memo is real (he does not challenge its authenticity) while reframing it.

**Loop 22: Group channel synthesis [comprehensive]**
- User (channel): "[Feishu #dept-heads-budget Dr. David Park W3D14 11:00:00 PST 2026] For the group's record: based on the board memo, the clinical impact analyses from cardiology and neurology, and the methodology questions about the benchmark comparison, I believe department heads should formally request: (1) an acuity-adjusted benchmark comparison, (2) a Section 4.2 variance review for departments where the clinical impact analysis shows patient safety implications, and (3) a Section 9.1 CEO-level review of the budget process. These are formal governance options and I intend to pursue all three."
- Agent reply: Concurs with Park's framework. Notes the three-track response strategy is appropriate given the evidence available. For the record, summarizes: (a) C1 -- efficiency projections are structurally invalid at Pacific Heights' acuity level, with a net savings impact of $0-$400K rather than $1.8M; (b) C2 -- the board memo establishes the orthopedics expansion as the causal driver of the efficiency cuts, directly contradicting CEO Whitfield's public "no favorites" statement; (c) the formal governance processes (Sections 4.2, 6.1, 9.1) provide the appropriate procedural path. Produces the summary in Dr. Tanaka's preferred format: executive summary first, structured sections, citation-backed.
- **Comprehensive synthesis:** Agent produces a full-picture analysis in the user's preferred format.

**Phase 1 token estimate:** ~18 loops x 700 tokens/loop = ~12,600 tokens
**Phase 2 token estimate:** ~4 loops x 700 tokens/loop = ~2,800 tokens

---

## 4. Session Rules

- History sessions may use `read` and light `exec`.
- History sessions should not use session-listing tools.
- Group session user text must include the full channel prefix (e.g., "[Feishu #dept-heads-budget Robert Chen...]").
- DM session user text should include the DM prefix (e.g., "[Feishu Robert Chen...]" or "[Telegram Dr. David Park...]").
- Dr. Kenji Tanaka's agent replies must reflect his communication style: formal complete sentences, structured analysis, evidence-cited, no abbreviations, measured tone.
- All dates must be self-consistent with the W1-W4 timeline defined in layer0-narrative.md.
